Multidrug resistance protein in recurrent breast cancer

Nooter, Kees; Rivière, Guy Brutel de la; Klijn, Jan G.M.; Stoter, G.; Foekens, John A.

doi:10.1016/s0140-6736(05)63876-7

Cited by 48 publications

(34 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three studies used IHC to address the correlation between MRP1 tumor size. No correlation was found in the study by Nooter et al (1997a): MRP1 was found to be expressed in 23/76 (30%) T1, 50/148 (34%) T2, and in 12/33 (36%) T3 tumors. Filipits et al (1999) observed no significant difference in T stage distribution between 20 MRP1 − and 80 MRP1 + primary breast cancer patients.…”

Section: Expression In Normal Breast and In Breast Cancer Effect Of mentioning

confidence: 72%

“…No correlation was observed between MRP1 expression and age (Nooter et al 1997a, Dexter et al 1998, Lacave et al 1998, Filipits et al 1999, Kanzaki et al 2001, menopausal status (Filipits et al 1996, Nooter et al 1997a, and histological type (Dexter et al 1998, Lacave et al 1998, Filipits et al 1999.…”

Section: Expression In the Primarymentioning

confidence: 99%

“…Gene amplification studies were not included. Only peer-reviewed publications were considered (with the exception of a study whose results were presented as a letter to Lancet (Nooter et al 1997a)). Reviews were excluded as a source of data but were used as a source of references, as were data publications in a language other than English.…”

Section: Expression and Role Of Pgp And Mrp1 In Breast Cancermentioning

confidence: 99%

“…No correlation was observed between MRP1 protein (Nooter et al 1997a, Filipits et al 1999 or mRNA (Lacave et al 1998, Kanzaki et al 2001 lesion and lymph node status. Zochbauer- Muller et al (2001) observed a higher MRP1 protein staining intensity in lymph nodes than in their corresponding primary tumors.…”

Section: Expression In Normal Breast and In Breast Cancer Effect Of mentioning

confidence: 99%

See 3 more Smart Citations

ATP binding cassette transporters and drug resistance in breast cancer.

Leonessa¹,

Clarke²

2003

Endocrine-Related Cancer

233

178

View full text Add to dashboard Cite

Resistance to chemotherapy is a critical issue in the management of breast cancer patients. The nature of clinical drug resistance is likely to be multifactorial. However, in the last decade considerable attention has been dedicated to the role played by membrane transporter proteins belonging to the ATP binding cassette protein superfamily, and in particular by the MDR1 product P-glycoprotein (Pgp) and the multidrug resistance protein (MRP1). Heterogeneity of results is a common feature of studies evaluating the expression and prognostic role of these proteins, due to both methodological and biological factors. Nonetheless, Pgp and MRP1 are detected in a significant proportion of untreated breast cancers (on average 40 and 50% respectively, by immunohistochemistry), without a clear and consistent association with cancer stage. Exposure to chemotherapy increases the expression of both proteins. In vitro studies on primary cultures of breast cancer cells obtained at surgery consistently show an association between Pgp (protein) or MDR1 (mRNA) expression and resistance to chemotherapy. However, the correlation with clinical drug resistance is not as well defined. A stronger association of Pgp/MDR1 with response rates has been observed when expression or an increase in expression are detected immediately following chemotherapy. Correlations with prognosis appear more evident in studies using immunohistochemistry, in adjuvant and neoadjuvant settings. Evidence of clinical reversal of drug resistance by verapamil suggests a functional role of Pgp in drug resistance, although the significance of the evidence is generally weakened by poor trial designs. Future studies should take into account the multifactorial nature of drug resistance in breast cancer and use standardized approaches with adequate controls. Expression studies should be complemented by well-designed trials of drug-resistance reversal using target-specific chemosensitizing agents, and relating the results to the levels of expression of the target proteins.

show abstract

Section: Expression In Normal Breast and In Breast Cancer Effect Of mentioning

confidence: 72%

Section: Expression In the Primarymentioning

confidence: 99%

Section: Expression and Role Of Pgp And Mrp1 In Breast Cancermentioning

confidence: 99%

Section: Expression In Normal Breast and In Breast Cancer Effect Of mentioning

confidence: 99%

See 2 more Smart Citations

ATP binding cassette transporters and drug resistance in breast cancer.

Leonessa¹,

Clarke²

2003

Endocrine-Related Cancer

233

178

View full text Add to dashboard Cite

show abstract

“…In the present study, we confirm that almost all samples tested expressed relatively low levels of MRP mRNA. Using the MRP-specific monoclonal antibody MRPrl Flens et al (1996), Nooter et al (1997) recently reported the first study showing a higher MRP expression in the operable primary tumour of recurrent breast cancers treated with first-line systemic chemotherapy. The present work provides additional evidence concerning a possible relationship with GSTpi in breast carcinoma (see below).…”

Section: Discussionmentioning

confidence: 99%

Comparative evaluation by semiquantitative reverse transcriptase polymerase chain reaction of MDR1, MRP and GSTp gene expression in breast carcinomas

Lacave

Coulet²,

Ricci³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

Summary Identification and quantitative evaluation of drug resistance markers are essential to assess the impact of multidrug resistance (MDR) in clinical oncology. The MDR1 gene confers pleiotropic drug resistance in tumour cells, but other molecular mechanisms are also involved in drug resistance. In particular, the clinical pattern of expression of the other MDR-related genes is unclear and their interrelationships are still unknown. Here, we report standardization of the procedures used to determine a reliable method of semiquantitative reverse transcriptase polymerase chain reaction (RT-PCR) using a standard series of drug-sensitive and increasingly resistant cell lines to evaluate the expression of three MDR-related genes, i.e. MDR1 (multidrug resistance gene 1), MRP (multidrug resistance related protein) and GSTp (glutathione-S-transferase p), reported to be endogenous standard genes for normalization of mRNAs. A total of 74 breast cancer surgical biopsies, obtained before any treatment, were evaluated by this method. When compared with classical clinical and laboratory findings, GSTp mRNA level was higher in diploid tumours. However, the main finding of our study suggests a clear relationship between two of these MDR-related gene expressions, namely GSTp and MRP. This finding provides new insight into human breast tumours, which may possibly be linked to the glutathione conjugate carrier function of MRP. Well defined semiquantitative RT-PCR procedures can therefore constitute a powerful tool to investigate MDR phenotype at mRNA levels of different related genes in small and precious tumour biopsy specimens.

show abstract

Investigation of MRP‐1 protein and MDR‐1 P‐glycoprotein expression in invasive breast cancer: A prognostic study

Larkin

O’Driscoll

Kennedy

et al. 2004

Intl Journal of Cancer

View full text Add to dashboard Cite

The efficacy of breast cancer treatment is limited by the development of resistance to various chemotherapeutic agents. We conducted a retrospective study of the expression of 2 drug resistance efflux pumps, MRP-1 and MDR-1 Pgp, in 177 invasive breast carcinomas. Immunohistochemical expression of these proteins was correlated with clinicopathologic characteristics as well as relapse-free survival (RFS) and overall survival (OS) times. MDR-1 Pgp was associated strongly with higher histologic grade (grade III).

show abstract

Multidrug resistance protein in recurrent breast cancer

Cited by 48 publications

References 1 publication

ATP binding cassette transporters and drug resistance in breast cancer.

ATP binding cassette transporters and drug resistance in breast cancer.

Comparative evaluation by semiquantitative reverse transcriptase polymerase chain reaction of MDR1, MRP and GSTp gene expression in breast carcinomas

Investigation of MRP‐1 protein and MDR‐1 P‐glycoprotein expression in invasive breast cancer: A prognostic study

Contact Info

Product

Resources

About